New data shed light on potential advantages of pacritinib for patients with myelofibrosis
Compared with standard therapy, pacritinib significantly reduces spleen size among people with myelofibrosis who have very low levels of platelets, according to a late-breaking study being presented today during the 58th ...
Dec 6, 2016
0
0